Volta Medical
- Industry
- Medical Equipment Manufacturing
- Founded Year
- 2016
- Headquarters
- Marseille, France
- Employee Count
- 100
Key People
- Theophile Mohr Durdez - CEO
- Matthieu Leclercq - Co-founder
- Vincent Audebert - Co-founder
- Herv Leclercq - Co-founder
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The founding team comprises individuals with over a decade of experience in their respective fields, bringing a blend of medical and technical expertise.
The founders' combined experience in medicine and technology provides a solid foundation for developing innovative solutions in cardiac electrophysiology.
- Clinical Need
-
Aspect: Very Strong
Summary: There is a significant unmet need for advanced tools to assist in the treatment of complex arrhythmias, particularly persistent atrial fibrillation.
Persistent atrial fibrillation is challenging to treat, and existing methods have limitations. An AI-driven solution like VX1 could enhance the precision and efficacy of ablation procedures.
- Competition
-
Aspect: Somewhat crowded
Summary: The electrophysiology devices market is competitive, with several established players offering various solutions.
Major companies like Boston Scientific and Medtronic have a strong presence in the electrophysiology market, necessitating a clear value proposition for new entrants.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing AI-driven software for real-time cardiac mapping presents moderate technical challenges.
Integrating AI into medical procedures requires rigorous validation to meet regulatory standards and gain clinician trust.
- Patent
-
Aspect: Strong
Summary: Volta Medical holds patents for its AI-driven electrophysiology solutions.
Patents covering the unique aspects of VX1 can prevent competitors from replicating the technology, securing market position.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
Investments from firms like Gilde Healthcare and Bpifrance provide the financial resources needed for clinical trials, regulatory approvals, and commercialization efforts.
- Regulatory
-
Aspect: Pivotal Trial
Summary: VX1 is undergoing pivotal clinical trials to demonstrate safety and efficacy.
Pivotal trials are essential for obtaining CE marking in Europe and FDA approval in the U.S., which are prerequisites for commercial distribution.
Opportunity Rollup
- Odds of Success
- 3.85
- Peak Market Share
- 5.6
- Segment CAGR
- 10.4%
- Market Segment
- Electrophysiology Devices
- Market Sub Segment
- AI-driven Cardiac Mapping Software
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.28 |
| 2 | 0.84 |
| 3 | 1.96 |
| 4 | 3.92 |
| 5 | 5.60 |
Key Takeaway
Volta Medical's AI-driven VX1 addresses a significant clinical need in arrhythmia treatment, but success depends on differentiating in a competitive market and navigating regulatory pathways.